Brief: Prothena Announces Novo Nordisk Obtains Fast Track Designation From The U.S. FDA For Coramitug
27/04/2026 21:07
April 27 (Reuters) - Prothena Corporation PLC PRTA.O: PROTHENA ANNOUNCES NOVO NORDISK OBTAINS FAST TRACK DESIGNATION FROM THE U.S. FDA FOR CORAMITUG (PRX004) IN ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY PROTHENA CORPORATION PLC - CORAMITUG PHASE 3 CLEOPATTRA TRIAL ENROLLS ~1,280 PARTICIPANTS; PRIMARY COMPLETION EXPECTED IN 2029 Source text: ID:nBw1cbWfVa Further company coverage: PRTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prothena
See all newsProthena posts Q1 revenue surge fueled by $50 million Novo Nordisk milestone payment
Brief: Prothena Q1 Net Income USD 32.721 Million
Brief: Prothena Announces Novo Nordisk Obtains Fast Track Designation From The U.S. FDA For Coramitug
Prothena Q4 net loss narrows
Brief: Prothena Announces Poster Presentation On Its TDP-43 Cytope® Program At Neuroscience 2025